卫宁健康(300253) - 2022 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2022 was ¥445,524,588.55, representing a 29.25% increase compared to ¥344,702,672.33 in the same period last year[3] - Net profit attributable to shareholders was ¥31,763,439.87, a significant increase of 121.73% from ¥14,325,009.37 year-on-year[3] - The net profit after deducting non-recurring gains and losses reached ¥30,571,630.00, up 3,842.44% from ¥775,449.63 in the previous year[3] - Basic earnings per share increased to ¥0.0148, reflecting a growth of 120.90% from ¥0.0067 in the same quarter last year[3] - The company achieved operating revenue of 445.52 million yuan, a year-on-year increase of 29.25%[20] - Net profit attributable to shareholders reached 31.76 million yuan, up 121.73% year-on-year[20] - Operating profit for the period was CNY 23,204,986.50, compared to a loss of CNY 9,272,542.09 in the same period last year[36] - The total profit for the current period is 23,239,854.13, compared to a loss of 9,295,883.48 in the previous period[39] Cash Flow and Assets - The company's cash flow from operating activities showed a net outflow of ¥98,677,812.85, which is a 50.27% improvement compared to a net outflow of ¥198,421,096.06 last year[3] - Cash inflow from operating activities is 609,221,525.20, compared to 508,016,329.70 in the previous period[43] - The net cash flow from operating activities is -98,677,812.85, an improvement from -198,421,096.06 in the previous period[43] - Cash outflow from investing activities is 116,767,377.82, compared to 80,661,779.08 in the previous period[46] - The ending cash and cash equivalents balance is 1,323,548,815.79, down from 1,595,178,998.93 in the previous period[46] - Total assets at the end of the reporting period were ¥7,459,281,143.39, a slight decrease of 0.49% from ¥7,496,296,725.89 at the end of the previous year[3] - Total liabilities increased to CNY 2,359,088,558.02 from CNY 2,322,891,629.90, reflecting a rise of 1.5%[32] - Cash and cash equivalents were not explicitly mentioned, but the total current assets decreased to CNY 4,085,670,171.05 from CNY 4,174,886,185.02[32] Shareholder Structure and Governance - The total number of restricted shares at the beginning of the period was 335,717,400, with 37,062,779 shares released and 487,500 shares added, resulting in 299,142,121 restricted shares at the end of the period[19] - The largest shareholder, Zhou Wei, had 164,478,181 restricted shares at the beginning, with 32,122,500 shares released, leaving 132,355,681 restricted shares[19] - Liu Ning had 81,707,212 restricted shares at the beginning, with 3,997,500 shares released, resulting in 77,709,712 restricted shares at the end of the period[19] - The company has a significant number of shares held by major shareholders, indicating strong insider ownership and potential alignment with shareholder interests[19] - The report indicates that the company is subject to various lock-up agreements for its executives and major shareholders, which may impact share liquidity[19] - The total number of shares held by the top shareholders reflects a concentrated ownership structure, which could influence corporate governance and decision-making[19] - The release of restricted shares may affect the stock price and market perception of the company as these shares become available for trading[19] - The company’s governance structure includes lock-up provisions for directors and senior executives, which is a common practice to ensure stability in shareholding[19] - The data suggests that the company is managing its shareholder structure actively, with periodic adjustments to restricted shares[19] - The overall trend in restricted shares indicates a gradual release, which may signal confidence in the company's future performance and stability[19] Expenses and Investments - The company reported a 200% increase in financial expenses, mainly due to interest accrued on convertible bonds during the reporting period[7] - The company experienced a 113.11% increase in non-operating income, primarily from government subsidies unrelated to daily operations[7] - Research and development expenses were CNY 66,198,838.64, an increase from CNY 62,897,860.31 year-over-year[36] - Government subsidies received during the reporting period amounted to 35.38 million yuan, approximately 9.36% of the net profit attributable to shareholders for the previous year[24] - The company utilized 80.33 million yuan of raised funds for convertible bond projects, with a cumulative usage of 454.78 million yuan[22] - The internet healthcare business revenue grew by 48.81%, accounting for 17.51% of total revenue[20] - The core product software sales and technical service revenue accounted for 73.90% of total revenue, growing by 41.33%[20] - New contract orders in the medical information business increased by over 35% compared to the previous year, with 15 projects valued at over 10 million yuan[20]